AMARIN CORP PLC -ADR (AMRN)
US0231112063 - ADR
Taking everything into account, AMRN scores 3 out of 10 in our fundamental rating. AMRN was compared to 565 industry peers in the Biotechnology industry. The financial health of AMRN is average, but there are quite some concerns on its profitability. AMRN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AMRN has reported negative net income.
AMRN had a negative operating cash flow in the past year.
In the past 5 years AMRN reported 4 times negative net income.
AMRN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
AMRN has a better Return On Assets (-5.24%) than 90.20% of its industry peers.
AMRN's Return On Equity of -7.40% is amongst the best of the industry. AMRN outperforms 91.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.24% | ||
| ROE | -7.4% | ||
| ROIC | N/A |
ROA(3y)-6.11%
ROA(5y)-4.55%
ROE(3y)-9.11%
ROE(5y)-6.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AMRN has a Gross Margin of 56.46%. This is in the better half of the industry: AMRN outperforms 79.68% of its industry peers.
In the last couple of years the Gross Margin of AMRN has declined.
AMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.31%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
AMRN has more shares outstanding than it did 1 year ago.
AMRN has more shares outstanding than it did 5 years ago.
AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
AMRN has an Altman-Z score of -1.55. This is a bad value and indicates that AMRN is not financially healthy and even has some risk of bankruptcy.
AMRN has a Altman-Z score (-1.55) which is in line with its industry peers.
There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.55 |
ROIC/WACCN/A
WACC7.19%
2.3 Liquidity
A Current Ratio of 3.23 indicates that AMRN has no problem at all paying its short term obligations.
AMRN has a Current ratio of 3.23. This is in the lower half of the industry: AMRN underperforms 63.46% of its industry peers.
AMRN has a Quick Ratio of 2.11. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
AMRN has a Quick ratio of 2.11. This is in the lower half of the industry: AMRN underperforms 74.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.23 | ||
| Quick Ratio | 2.11 |
3. Growth
3.1 Past
AMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.77%, which is quite impressive.
The Revenue for AMRN has decreased by -25.26% in the past year. This is quite bad
Measured over the past years, AMRN shows a small growth in Revenue. The Revenue has been growing by 6.01% on average per year.
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)-25.26%
Revenue growth 3Y-20.64%
Revenue growth 5Y6.01%
Sales Q2Q%-35.97%
3.2 Future
The Earnings Per Share is expected to grow by 38.30% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 13.06% on average over the next years. This is quite good.
EPS Next Y0.43%
EPS Next 2Y-23.69%
EPS Next 3Y5.5%
EPS Next 5Y38.3%
Revenue Next Year-30.17%
Revenue Next 2Y-22.16%
Revenue Next 3Y-8.77%
Revenue Next 5Y13.06%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMRN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.69%
EPS Next 3Y5.5%
5. Dividend
5.1 Amount
AMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMARIN CORP PLC -ADR
NASDAQ:AMRN (11/12/2024, 9:59:53 AM)
0.5533
-0.01 (-1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap227.50M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.24% | ||
| ROE | -7.4% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.46% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.23 | ||
| Quick Ratio | 2.11 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y0.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-25.26%
Revenue growth 3Y-20.64%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y